Succès de l’introduction en Bourse d’ONCODESIGN sur Alternext


Paris – 2 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs , today extended warm congratulations to Oncodesign, an innovative biotechnology company dedicated to discovering new approaches to cancer and other serious illnesses for which no effective treatments are known, on its successful admission to trading on Alternext in Paris.

Founded by Philippe Genne in Dijon in 1995, Oncodesign is dedicated to accelerating the discovery of new, personalized and effective treatments for patients suffering from cancer. The company’s business model centres on two strategic activities: (1) experimentation through preclinical evaluation of new anticancer therapies on behalf of pharmaceutical and biotech companies, and (2) discovery of new therapeutic molecules, in particular a new generation of kinases, working independently or in partnership with large pharma groups such as Sanofi, Ipsen and UCB. To achieve these goals,  Oncodesign draws on cutting-edge solutions that combine science and technology. The company holds a unique position within its market, including solid recognition from over 500 clients around the globe.

Oncodesign (ticker symbol: ALONC) was listed through the admission to trading of 4,390,640 existing shares making up the company’s equity and the sale of 1,749,394 new shares issued under a Global Offering , including full exercise of the extension option. The over-allotment option was also fully exercised, with 77,882 shares sold.

The offering was a resounding success with French and international investors, both institutional and retail. Total demand was €23.5 million, including an €11.6 million Global Placement and an €11.9 million Open Price Public Offering. The IPO raised €12.8 million altogether, with 40% allocated to individual investors.
The admission and issue price of Oncodesign shares was set at €7.34 per share, at the high end of the indicative price range. The company’s market capitalisation stood at around €44.5 million on the issue date.

We welcome Oncodesign, an innovative international standard-setter in preclinical evaluation and discovery of anticancer treatments, to the market. The success of its IPO with both institutional investors and individuals illustrates the enormous appeal of biotech stocks. Oncodesign will benefit from the assistance of EnterNext’s experts and Euronext’s unique market model for both listing and trading. We are delighted to support the bold and innovative strategy of this company and the many fast-growing businesses listed on Euronext markets,” said Eric Forest, Chairman and CEO of EnterNext.

Oncodesign’s founder, Chairman and CEO Philippe Genne, added: “Our successful listing on Alternext Paris opens a new and critical stage in our growth. It has brought us both the financial resources we need and increased visibility to accelerate our discoveries of new, targeted anticancer therapies that will  help treat many patients.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.